Point72 Hong Kong LTD Mannkind Corp Transaction History

Point72 Hong Kong LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.67 - $4.77 $33,156 - $59,233	-12,418 Reduced 28.52%	31,130 $119,000
Q1 2022 May 16, 2022	BUY	$2.62 - $4.45 $80,289 - $136,370	30,645 Added 237.5%	43,548 $160,000
Q4 2021 Feb 14, 2022	BUY	$4.05 - $5.37 $1,089 - $1,444	269 Added 2.13%	12,903 $56,000
Q3 2021 Nov 15, 2021	BUY	$3.89 - $5.48 $49,146 - $69,234	12,634 New	12,634 $55,000
Q1 2019 May 15, 2019	SELL	$1.14 - $2.25 $16,837 - $33,232	-14,770 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.02 - $2.05 $15,065 - $30,278	14,770 New	14,770 $16,000
Q3 2018 Nov 14, 2018	SELL	$1.01 - $2.19 $11,143 - $24,162	-11,033 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$1.59 - $2.38 $17,542 - $26,258	11,033 New	11,033 $21,000

244

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.57B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.